{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:46:24Z","timestamp":1762782384119},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The complication profile following repeat <jats:sup>90<\/jats:sup>Y-radioembolization (RE) is not well understood, and repeat RE is sometimes avoided because of concerns for RE-induced liver disease (REILD) and liver toxicity. The purpose of this study was to examine the incidence of REILD and liver toxicity following repeat <jats:sup>90<\/jats:sup>Y-RE and to identify potential risk factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective analysis of patients undergoing repeat RE to the same hepatic lobe between 2013 and 2018 was performed. Baseline factors were evaluated as predictors of liver toxicity, mortality, and REILD, which was defined as the presence symptomatic ascites or jaundice in the absence of biliary obstruction within 8 weeks following RE. Post-RE complications were graded according to the Common Terminology Criteria for Adverse Events version 5.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 39 patients underwent repeat RE with 14 (35.9%) experiencing Common Terminology Criteria for Adverse Events toxicity of grade 2 or greater, 3 (10.3%) grade 3, and no grade 4 or greater. A Model for End Stage Liver Disease score of 8 or greater was associated with grade 2 toxicity or greater (26.7% vs 75%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.013). Only 3 patients (7.7%) experienced REILD due to symptomatic ascites without jaundice. Greater than 2 REs were associated with a greater rate of 6-month mortality (12% vs 58.3%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003), 12-month mortality (28% vs 75%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007), and REILD (0% vs 21.4%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.016). Age, sex, microsphere type, cirrhosis, Child-Pugh, and Eastern Cooperative Oncology Group status were not significantly associated with complications, REILD, or survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Repeat <jats:sup>90<\/jats:sup>Y-RE appears to be well tolerated with a low rate of high-grade adverse events and REILD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002828","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T19:40:22Z","timestamp":1577216422000},"page":"100-104","source":"Crossref","is-referenced-by-count":16,"title":["Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization"],"prefix":"10.1097","volume":"45","author":[{"given":"Mohammad","family":"Elsayed","sequence":"first","affiliation":[{"name":"Interventional Radiology and Image-Guided Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Ermentrout","sequence":"additional","affiliation":[{"name":"Interventional Radiology and Image-Guided Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ila","family":"Sethi","sequence":"additional","affiliation":[{"name":"Interventional Radiology and Image-Guided Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary L.","family":"Bercu","sequence":"additional","affiliation":[{"name":"Interventional Radiology and Image-Guided Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Galt","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Whitmore","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Brandon","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[{"name":"Interventional Radiology and Image-Guided Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1055\/s-0035-1564708","article-title":"Planning arteriography for yttrium-90 microsphere radioembolization","volume":"32","year":"2015","journal-title":"Semin Intervent Radiol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.tvir.2007.08.001","article-title":"Technical aspects of radioembolization with 90Y microspheres","volume":"10","year":"2007","journal-title":"Tech Vasc Interv Radiol"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","year":"2010","journal-title":"Gastroenterology"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0033-1333649","article-title":"Intra-arterial therapies for metastatic colorectal cancer","volume":"30","year":"2013","journal-title":"Semin Intervent Radiol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00270-009-9658-8","article-title":"Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases","volume":"32","year":"2009","journal-title":"Cardiovasc Intervent Radiol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","article-title":"Radioembolization-induced liver disease: a systematic review","volume":"29","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"bib9-20230925","first-page":"152","article-title":"Monitoring of total and regional liver function after SIRT","volume":"4","year":"2014","journal-title":"Front Oncol"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.26191","article-title":"Prognostic factors and prevention of radioembolization-induced liver disease","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/COC.0b013e3181df0a50","article-title":"Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations","volume":"34","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/COC.0b013e31827deea1","article-title":"Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors","volume":"37","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1023\/A:1013569329846","article-title":"Randomised trial of SIR-Spheres\u00ae plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer","volume":"12","year":"2001","journal-title":"Ann Oncol"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2407-5-132","article-title":"A prospective evaluation of treatment with selective internal radiation therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy","volume":"5","year":"2005","journal-title":"BMC Cancer"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2967\/jnumed.113.127662","article-title":"Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2013.05.041","article-title":"Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy","volume":"87","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00270-013-0547-9","article-title":"Safety of repeated yttrium-90 radioembolization","volume":"36","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jvir.2007.07.016","article-title":"Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma","volume":"18","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jvir.2011.06.006","article-title":"Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center","volume":"22","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1148\/rg.2015140314","article-title":"(90)Y radioembolization: multimodality imaging pattern approach with angiographic correlation for optimized target therapy delivery","volume":"35","year":"2015","journal-title":"Radiographics"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors: description and possible risk factors","volume":"112","year":"2008","journal-title":"Cancer"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jvir.2011.09.028","article-title":"Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients","volume":"23","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"bib26-20230925","first-page":"469","article-title":"Radioembolization with yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma","volume":"6","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"bib27-20230925","first-page":"19","article-title":"Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics","volume":"4","year":"2012","journal-title":"Hepat Med"},{"key":"bib28-20230925","first-page":"231","article-title":"Repeated treatment with (90)Y-microspheres in intrahepatic cholangiocarcinoma relapsed after the first radioembolization","volume":"34","year":"2019","journal-title":"Cancer Biother Radiopharm"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00270-018-1949-5","article-title":"Hepatotoxic dose thresholds by positron-emission tomography after yttrium-90 radioembolization of liver tumors: a prospective single-arm observational study","volume":"41","year":"2018","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:06:14Z","timestamp":1695621974000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002828"}},"subtitle":["Outcomes at a Large Tertiary Care Center"],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002828","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,24]]}}}